Intradigm (Palo Alto, CA) an early-stage developer of RNAi therapeutics with an initial focus on oncology, closed a $2.9M Series, bringing the round total to $21.4M. Participants include Astellas Venture Management, Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Funds.